摘要
目的:探讨氧自由基(OFR)和血栓素A2(TXA2)、前列环素(PGI2)在肺缺血再灌注损伤(IRI)中的作用以及三七总皂甙对其影响。方法:复制在体兔肺IRI模型。30只日本大耳兔,随机均分为三组:假手术组(S组)、缺血再灌注组(IR组)和缺血再灌注+三七总皂甙注射液组(PSN组)。检测血清超氧化物歧化酶(SOD)活性、黄嘌呤氧化酶(XO)活性和丙二醛(MDA)浓度,测定肺组织TXB2、6-keto-PGF1 α含量与比值的变化。结果:IR组血清XO、MDA均显著高于S组,SOD明显低于S组(均P<0.05和P<0.01)。 IR组肺组织TXB2显著高于S组(P<0.01),6-keto-PGF1α差异无明显;PNS组与IR组相比TXB2均下降非常明显(P<0.01),TXB2/6-keto-PGF1α降低很显著(P<0.01),与IR组相比差异有显著性(P<0.05和 P<0.01)。结论:三七总皂甙能降低氧自由基水平,抑制血小板释放TXA2,调控TXA2/PGI2的平衡,通过遏制无复流现象,减轻肺IRI。
Objective: To explore the role of oxygen free redicals(OFR), TXA2 and PGI2 in lung ischemia and reperfusion injury (IRI) and effect of Panax notoginsenosides injection on them. Methods: Rabbit lung model of ischemia reperfusion injury was constituted in vivo. Thirty rabbits were divided into three groups randomly: sham-operatlon group(group S), ischemia reperfusion group(group IR) and ischemia reperfusion plus panax notoginsenosides injection(group PNS). Malondialdehyde (MDA),superoxide dismutase (SOD) and xanthine oxidase (XO) in serum were measured, and TXB2 and 6-keto-PGF1 α levels in lung tissue were separately measured with radioimmunoassay. Results: in IR group, XO and MDA increased and SOD decreased in serum, while the same changes happened in PI group but less severely. TXB2 levels in lung increased significantly (P〈0.01) while 6-keto-PGF1α shad not any remarkable change during lung ischemia-reperfusion compared with the S group. For the SI group protected with panax notoginsenosldes, as compared with IR group, TXB2 levels decreased very significantly (P〈0.01), TXB2/6-keto-PGF1 α decreased very remarkably (P〈 0.01). Conclusion: 0FR is an important factor during IRI, panax notoginsenosides may attenuate lung ischemia- reperfusion injury through dropping 0FR level and antagonizing oxidative stress, and inhibit platelet to release TXA2, regulate TXA2/ PGI2 balance and restrain no-fellow phenomenon, so that it has the protective effects on postischemia reperfusion lung. Prostacyclin;
出处
《温州医学院学报》
CAS
2006年第1期23-25,共3页
Journal of Wenzhou Medical College
基金
浙江省卫生厅科研基金资助项目(SWS00021)。